Chemical Namebelzutifan
Dosage FormTablets (oral; 40 mg)
Drug ClassInhibitors
SystemUrinary, Nervous, Endocrine
CompanyMerck & Co.
Approval Year2021


  • For the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery
Last updated on 3/15/2022

More on this drug: Clinical Trials

Document TitleYearSource
Welireg (belzutifan) Prescribing Information.2021Merck & Co. Inc., Whitehouse Station, NJ

Have we missed a study, or would you like to comment on a study?